Sign In
Buy HALO
$82.54
-0.760 (-0.91%)
At Close: Jul 31, 2026
Capital Fund Management S.A. Makes New $5.61 Million Investment in Halozyme Therapeutics, Inc. $HALO
04:16am, Monday, 01'st Dec 2025
Capital Fund Management S.A. purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ: HALO) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Com
Advisors Asset Management Inc. Sells 2,191 Shares of Halozyme Therapeutics, Inc. $HALO
03:17am, Monday, 01'st Dec 2025
Advisors Asset Management Inc. lessened its position in shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 8.5% in the second quarter, according to the company in its most recent 13F filing with
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
10:41am, Thursday, 27'th Nov 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Halozyme to Participate in the 8th Annual Evercore Healthcare Conference
08:30am, Tuesday, 25'th Nov 2025
SAN DIEGO , Nov. 25, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present and host i
Creative Planning Sells 14,890 Shares of Halozyme Therapeutics, Inc. $HALO
03:57am, Tuesday, 25'th Nov 2025
Creative Planning trimmed its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 22.7% in the second quarter, according to the company in its most recent filing with the SEC. The inst
Brandywine Global Investment Management LLC Sells 1,531 Shares of Halozyme Therapeutics, Inc. $HALO
04:16am, Monday, 24'th Nov 2025
Brandywine Global Investment Management LLC reduced its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 2.1% in the second quarter, according to its most recent disclosure with the Se
Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery
08:50am, Tuesday, 18'th Nov 2025
Royalty revenue contribution expected to begin as early as 2030 Initial partner targets include derisked MoAs that are approved blockbusters today Highly scalable licensing model and long duration IP
Why I Keep Buying These 10 Incredible Growth Stocks
08:45am, Monday, 17'th Nov 2025
These companies have bright futures and offer the potential for decades of share price appreciation.
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab
07:00am, Monday, 17'th Nov 2025
SAN DIEGO and UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Nov. 17, 2025 /PRNewswire/ -- Merus N.V.
Allworth Financial LP Has $489,000 Stock Holdings in Halozyme Therapeutics, Inc. $HALO
03:31am, Monday, 17'th Nov 2025
Allworth Financial LP raised its holdings in Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 607.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commis
FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma
08:30am, Friday, 07'th Nov 2025
DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology SAN DIEGO , Nov. 7, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced tha
SAN DIEGO , Nov. 6, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), today announced the pricing of $650 million aggregate principal amount of 0% converti
Renaissance Group Opens New $35M Position in Halozyme Therapeutics (NASDAQ: HALO): Why This Biotech Stock Is Worth a Look
05:12pm, Wednesday, 05'th Nov 2025
Renaissance Group acquired 478,735 shares of Halozyme Therapeutics; estimated $35.11 million trade based on quarterly average pricing. Transaction represents 1.32% of reported U.S. equity assets under
SAN DIEGO , Nov. 5, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), today announced that it intends to offer, subject to market conditions and other fact
Teacher Retirement System of Texas Has $1.73 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO
03:44am, Wednesday, 05'th Nov 2025
Teacher Retirement System of Texas cut its position in Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 2.7% during the undefined quarter, according to the company in its most recent disclosure with the
